Bausch Health Companies Inc. Operating Lease, Payments
Bausch Health Companies Inc. (BHC) reported Operating Lease, Payments of $86.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-19
- Bausch Health Companies Inc. operating lease, payments for the quarter ending 2019-12-31 was $17.00M.
- Bausch Health Companies Inc. operating lease, payments for the quarter ending 2019-09-30 was $17.00M.
- Bausch Health Companies Inc. operating lease, payments for the quarter ending 2019-06-30 was $19.00M.
- Bausch Health Companies Inc. operating lease, payments for the quarter ending 2019-03-31 was $20.00M.
- Bausch Health Companies Inc. operating lease, payments for fiscal 2025 was $86.00M, a 1.18% increase from fiscal 2024.
- Bausch Health Companies Inc. operating lease, payments for fiscal 2024 was $85.00M, a 16.44% increase from fiscal 2023.
- Bausch Health Companies Inc. operating lease, payments for fiscal 2023 was $73.00M, a 4.29% increase from fiscal 2022.
- Bausch Health Companies Inc. operating lease, payments for fiscal 2022 was $70.00M, a 7.89% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $86.00M 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $85.00M 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $73.00M 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $70.00M 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $76.00M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $74.00M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $17.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $34.00M derived: sum of 2 quarters · filed 2022-05-11 | $53.00M derived: sum of 3 quarters · filed 2022-05-11 | $73.00M 8-K · filed 2022-05-11 |
| 2019-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $36.00M derived: sum of 2 quarters · filed 2019-11-04 | $56.00M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $39.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $20.00M 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |